Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: Week 96 results from the ANRS 139 TRIO trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 5, 2012, Pages 489-493

  Fagard, Catherine ^a,m   Colin, Céline ^a,m   Charpentier, Charlotte ^b,c   Rami, Agathe ^d   Jacomet, Christine ^e   Yeni, Patrick ^b   Vittecoq, Daniel ^f   Katlama, Christine ^g,h   Molina, Jean Michel ⁱ   Descamps, Diane ^b,c   Chêne, Geneviève ^a,j,m   Yazdanpanah, Yazdan ^k,l  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k UNIV LILLE   (France)

^l UNIVERSITÉ DE LILLE   (France)

^m UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

Darunavir ritonavir; Etravirine; HIV; Multidrug resistant; Raltegravir

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; RITONAVIR; TRIACYLGLYCEROL;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL RESISTANCE; ANUS CARCINOMA; ARTICLE; CD4+ T LYMPHOCYTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EPIDERMOLYSIS; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MUSCLE SPASM; MUTATIONAL ANALYSIS; MYELOMA; NEPHROLITHIASIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES; RITONAVIR; RNA, VIRAL; SULFONAMIDES;

EID: 84859736535     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824bb720     Document Type: Article

References (11)

1. Taiwo B, Murphy RL, Katlama C, et al. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. Drugs; 2010. 70.
2. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49:1441-1449.
3. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antire-troviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-133. (Pubitemid 47482607)
4. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
5. Charpentier C, Roquebert B, Colin C, et al. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS. 2010;24:2651-2656.
6. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323-332.
7. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52:350-356.
8. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39-48.
9. Yazdanpanah Y, Chene G, Losina E, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001;30:864-871. (Pubitemid 32827397)
10. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination anti-retroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49: 1109-1116.
11. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-762.